NCT04189848

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

A Trial to Complare the Injection Site Pain Experience of Semaglutide 0.25 mg and Dulaglutide 0.75 mg Administered sc

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 104 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Conditions

• Healthy Volunteers
• Diabetes Mellitus, Type 2
• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Semaglutide	Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
DRUG	Dulaglutide	Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

Timeline

• Start date: 2019-12-03
• Primary completion: 2020-01-29
• Completion: 2020-02-27
• First posted: 2019-12-06
• Last updated: 2022-11-07
• Results posted: 2021-02-17

Locations

1 site across 1 country: Netherlands